Best Yumanity Therapeutics

November 18 2019 yumanity therapeutics appoints neuroscience veteran brigitte robertson m d as chief medical officer.

Best yumanity therapeutics. About yumanity therapeutics yumanity therapeutics is transforming drug discovery for neurodegenerative diseases. Yumanity therapeutics a small neuroscience focused startup co founded by longtime biotech executive tony coles is pairing up with pharma giant merck to develop new treatments for two neuro. Merck nyse mrk inks an agreement with privately held yumanity therapeutics for exclusive rights to two of the latter s pipeline candidates for amyotrophic lateral sclerosis als and. Yumanity therapeutics announces strategic research collaboration and license agreement with merck focused on accelerating the development of new treatments for neurodegenerative diseases.

Founded in december 2014 by award winning protein folding expert susan lindquist ph d and renowned biotech industry leader tony coles m d yumanity is working to identify and develop new disease modifying therapies that address several illnesses with critical unmet medical. The company is focused on discovering disease modifying therapies for patients with. We are passionate in. Yumanity therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding.

Yumanity therapeutics appoints neuroscience veteran brigitte robertson m d as chief medical officer. Yumanity therapeutics was founded in december 2014 to serve the millions of people affected by neurodegenerative diseases including alzheimer s disease parkinson s disease amyotrophic lateral sclerosis als also known as lou gehrig s disease. Robertson is chief medical officer at yumanity therapeutics. The company is focused on discovering disease modifying therapies for patients with parkinson s amyotrophic.

Senior research associate als ftld. Since then we have assembled a highly skilled team of scientists and innovators deeply. View more november 18 2019. Yumanity therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding.

While at shire as a therapeutic area head she successfully led a number of global development teams and was responsible for the disease area strategy and execution of shire s neuropsychiatry portfolio including programs in status epilepticus dravet. Yumanity therapeutics is transforming drug discovery for neurodegenerative diseases.